KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Payables (2016 - 2025)

Novavax has reported Payables over the past 16 years, most recently at $24.6 million for Q4 2025.

  • Quarterly results put Payables at $24.6 million for Q4 2025, down 40.89% from a year ago — trailing twelve months through Dec 2025 was $24.6 million (down 40.89% YoY), and the annual figure for FY2025 was $24.6 million, down 40.89%.
  • Payables for Q4 2025 was $24.6 million at Novavax, up from $15.2 million in the prior quarter.
  • Over the last five years, Payables for NVAX hit a ceiling of $710.7 million in Q2 2022 and a floor of $15.2 million in Q3 2025.
  • Median Payables over the past 5 years was $83.6 million (2023), compared with a mean of $168.1 million.
  • Biggest five-year swings in Payables: skyrocketed 4411.72% in 2021 and later tumbled 87.72% in 2023.
  • Novavax's Payables stood at $127.0 million in 2021, then soared by 326.13% to $541.4 million in 2022, then tumbled by 75.51% to $132.6 million in 2023, then tumbled by 68.65% to $41.6 million in 2024, then tumbled by 40.89% to $24.6 million in 2025.
  • The last three reported values for Payables were $24.6 million (Q4 2025), $15.2 million (Q3 2025), and $50.6 million (Q2 2025) per Business Quant data.